tradingkey.logo

Johnson & Johnson Says Rybrevant Longer-Term Results Show Promising And Durable Responses In Difficult-To-Treat Colorectal Cancer

ReutersJan 10, 2026 3:02 PM

- Johnson & Johnson JNJ.N:

  • RYBREVANT® (AMIVANTAMAB-VMJW) LONGER-TERM RESULTS SHOW PROMISING AND DURABLE RESPONSES IN DIFFICULT-TO-TREAT COLORECTAL CANCER

  • J&J - OVER 70% RESPONSE RATE IN FIRST-LINE SUBGROUP WITH AMIVANTAMAB

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI